Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.
about
Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer developmentAberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast CancerThe Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer PatientsRoles for miRNAs in endocrine resistance in breast cancerMechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNAGlobal microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG studyMicroRNAs in pathogenesis of breast cancer: Implications in diagnosis and treatment.Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.Hypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1.Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.Insulin-like growth factor-1 signaling regulates miRNA expression in MCF-7 breast cancer cell line.Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4.Clinical implications of microRNAs in cancer.MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistanceEpigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy.Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro.MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancerHypoxia-induced miR-15a promotes mesenchymal ablation and adaptation to hypoxia during lung development in chicken.Jumonji/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e.Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4.Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells.miRNAs and estrogen action.CDK4 and miR-15a comprise an abnormal automodulatory feedback loop stimulating the pathogenesis and inducing chemotherapy resistance in nasopharyngeal carcinoma.Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancerDelivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.The role of microRNAs in breast cancer migration, invasion and metastasisRegulation of the Wip1 phosphatase and its effects on the stress response.Current status and implications of microRNAs in ovarian cancer diagnosis and therapy.E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms.New developments in the treatment of HER2-positive breast cancerTherapeutic siRNA for drug-resistant HER2-positive breast cancer.Phosphorylation of estrogen receptor α at serine 118 is correlated with breast cancer resistance to tamoxifenA novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growthEndocrine resistance in breast cancer: Current status and a perspective on the roles of miRNAs (Review).MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression.miRNA clusters as therapeutic targets for hormone-resistant breast cancer.
P2860
Q22000752-0DAC3762-CE0E-41E8-ABB8-C4D1BE24FCE4Q26773907-2A0481E7-8114-4A3A-B853-6CD59FCF35A8Q26782449-C73B6B88-222B-47E2-B82C-F9F7E48E087EQ26783076-5954E563-C7FE-46E2-A65E-F510C346C5DBQ27011221-FAEFF832-E5E3-4A3D-AE30-AC60974CB488Q28729855-205286C9-AE9B-4A9A-891C-B95F22C330CEQ33585094-8DDA079A-589B-4C19-919F-F9F606B7DEA1Q33709971-29878C0A-4535-4120-9F05-19C6E12D712AQ33729914-AE05465B-777C-476E-90BC-F27F4D80D889Q33850064-006EFAFD-424B-404F-BE69-54AC83459737Q34504974-B462192C-0CA6-47FA-AB57-796BDEACAA07Q34506613-C932E6BF-24C7-45BE-9D6D-D8E6EF02B1A0Q34539750-F28DBFAC-4D50-4EEE-B1F2-8CCF51CDDDD9Q34570698-6CE94A6D-E000-4B07-B49D-93520046D24AQ34756694-2F00EF16-577A-4B1A-9B38-BB0CE0CA576DQ35039281-CCAFB0FC-0170-41EC-8EC8-28966B5B52D5Q35108358-85707615-0F95-4E4B-BDF9-05A8DE33C2F0Q35128098-942924AF-B2A3-4531-BB0C-F0D883DCED08Q35179724-6B52292C-43D4-4285-BADF-29237A04A9BAQ35562595-7AA138EC-224A-41A2-A1C8-80B0AFCA65FBQ35599629-261D3E01-AF27-4782-8BF5-24DCB37224D2Q35709636-2D6AC5AC-5659-4C08-9210-D56EA528BB51Q35906736-B839FB53-0550-48A7-AEEF-0EBCB2B69F93Q35946984-CEBA6582-9896-4833-A2FE-DD473A686482Q35963331-D4DD5264-B25A-4627-B8AB-9B8142627700Q36067934-D619D0CD-A532-4A87-8A21-6EFA4FC7A5D0Q36107033-99A0209B-0941-4480-90F2-81F45CB973C8Q36396579-E239E715-88EC-415E-9292-14954883131DQ36429982-4FD1B410-F1B1-48FB-90A5-FA11637A18A1Q36517492-CFB3D867-CB27-4F49-9BD1-F504B9CF7939Q36544743-9730D2CE-9D0C-4FEB-8FCC-56E4FCA2E052Q36589865-1B225E1D-A72F-40BA-8DAF-F9461F88789BQ36846329-FEFC4668-6351-4E0B-B60E-2FD3F96D6C39Q37016382-7F4CBA19-35D1-41EA-9C43-3E366F135A58Q37046699-652DE2B8-FCC3-469F-BEE4-25F781DC1105Q37092904-CE7D76E2-CC5D-45CF-AF50-D55774F14034Q37109741-F9C2B5DC-6066-43C1-8759-19002BC156F0Q37211627-A0048C5A-61FA-4194-A3DC-3BF71885B9F8Q37269100-B236FDAD-E507-4D1F-86AE-F5E35364A631Q37316805-0A5167DC-AD2B-4530-940A-82158F59DD9E
P2860
Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.
@ast
Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.
@en
Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.
@nl
type
label
Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.
@ast
Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.
@en
Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.
@nl
prefLabel
Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.
@ast
Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.
@en
Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.
@nl
P2093
P2860
P356
P1433
P1476
Oncogenic HER2{Delta}16 suppre ...... e resistance of breast tumors.
@en
P2093
Diana M Cittelly
Frank E Jones
Juan P Fonseca
Matthew E Burow
Partha M Das
Virgilio A Salvo
P2860
P304
P356
10.1093/CARCIN/BGQ192
P407
P577
2010-09-27T00:00:00Z